Yahoo · Sep 15, 2026
Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says
Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the re
NYSE · AZN
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
$161.85
Down-$1.93 (-1.18%)
Updated Sep 16, 2026, 11:08 AM
SID Score
7.1/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 279.95B
- P/E ratio
- 33.06
- Dividend yield
- 0.95%
- 52-week range
- $72.90 – $212.71
- Volume
- 2.94M
- Avg. volume
- 5.47M
Price performance
AZN price history
1M range · 20 trading sessions · Daily adjusted prices
AZN closed at $161.85 after 20 trading sessions, up 1.09% for the selected period.
- Last close
- $161.85
- Period change
- +1.09%
- Period low
- $156.94
- Period high
- $169.66
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $161.42 | $163.90 | $160.71 | $161.85 | 2.94M |
| Sep 14, 2026 | $164.08 | $164.55 | $162.14 | $163.78 | 3.09M |
| Sep 11, 2026 | $161.43 | $161.51 | $158.13 | $160.17 | 2.23M |
| Sep 10, 2026 | $157.68 | $160.30 | $157.23 | $159.64 | 2.94M |
| Sep 9, 2026 | $158.31 | $159.1301 | $156.74 | $156.94 | 3.87M |
| Sep 8, 2026 | $163.96 | $163.96 | $159.40 | $160.04 | 5.15M |
| Sep 4, 2026 | $162.82 | $163.78 | $161.13 | $162.70 | 3.07M |
| Sep 3, 2026 | $165.64 | $165.74 | $162.24 | $164.77 | 2.43M |
| Sep 2, 2026 | $162.54 | $164.69 | $160.87 | $161.63 | 3.3M |
| Sep 1, 2026 | $163.66 | $164.24 | $161.385 | $162.47 | 2.6M |
| Aug 31, 2026 | $162.70 | $163.75 | $161.95 | $162.13 | 3.07M |
| Aug 28, 2026 | $163.52 | $163.54 | $161.18 | $162.70 | 2.88M |
| Aug 27, 2026 | $165.27 | $165.58 | $163.98 | $164.52 | 2.5M |
| Aug 26, 2026 | $167.46 | $167.89 | $165.17 | $166.27 | 2.68M |
| Aug 25, 2026 | $167.08 | $170.18 | $166.78 | $169.66 | 3.45M |
| Aug 24, 2026 | $164.57 | $167.08 | $163.97 | $166.71 | 2.78M |
| Aug 21, 2026 | $164.04 | $167.25 | $163.96 | $165.98 | 3.18M |
| Aug 20, 2026 | $163.40 | $165.57 | $161.475 | $164.49 | 5.09M |
| Aug 19, 2026 | $162.13 | $165.91 | $162.00 | $164.95 | 3.82M |
| Aug 18, 2026 | $159.12 | $160.64 | $158.98 | $160.10 | 3M |
Latest AZN news
The latest Smart Investors Daily articles mentioning AZN.
Stock researchCompany · Overview
AZN research
Overview
Company profile and research snapshot.
Company profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $102.67
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Berenberg Bank | Buy | — |
| Jun 26, 2026 | Deutsche | Sell | — |
| Jun 26, 2026 | Jefferies | Buy | — |
| Jun 11, 2026 | Deutsche | Sell | — |
| Jun 9, 2026 | Jefferies | Buy | — |
News briefing
Generated Sep 15, 2026, 9:03 PM
Why Is AZN Down Today?
AstraZeneca shares declined 1.18% today as mixed signals from the company's oncology pipeline weighed on investor sentiment. While the healthcare sector posted premarket gains, AZN's recent clinical trial setbacks appear to be offsetting any broader market tailwinds for the pharmaceutical giant.
Bottom line: AstraZeneca's 1.18% decline reflects justified market concern over the Etcamah breast cancer study failure, which significantly narrows the commercial opportunity for a recently approved asset in a competitive oncology market. While two other pipeline wins provide some offsetting positive news, investors should monitor upcoming oncology trial results closely as the key catalyst for recovery, particularly given the sector's execution-dependent nature and AZN's reliance on pipeline success for growth.
Yahoo · Sep 15, 2026
AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss
AstraZeneca PLC (NYSE:AZN)’s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, dealing a setback to one of the company’s key oncology growth opportunities. The trial evaluated Etcamah plus Pfizer’s Ibrance (palbociclib) in previously untreated patients with ER-positive, HER2-negative advanced breast cancer and found a numerical improvement […]
Yahoo · Sep 15, 2026
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
Yahoo · Sep 15, 2026
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search processBRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026. Ingrid Zhang succeeds Alan Bash, who has served as Interim Chief Execut
AI research layers
Interpretive context generated from the platform’s current data sources.
AstraZeneca PLC Stock Performance
AstraZeneca PLC shares currently trade at $161.85, reflecting a robust 102.67% gain over the trailing twelve months, per SID market data. However, shorter-term momentum has been mixed, with a 4.16% gain over the past month offset by an 8.37% decline over the past three months. The stock sits below both its 50-day moving average of $166.15 and is nearly in line with its 200-day moving average of $162.12, suggesting a recent pullback within a longer-term uptrend. The 14-day relative strength index stands at 45.0, placing AZN in neutral territory and indicating neither overbought nor oversold conditions. AstraZeneca carries a notably low beta of 0.168, according to Massive/Polygon data, underscoring its defensive characteristics relative to the broader market. Average daily trading volume registers at approximately 5.47 million shares, supporting adequate liquidity for institutional participants across the healthcare sector.
AstraZeneca PLC Valuation Analysis
AstraZeneca PLC commands a market capitalization of approximately $279.9 billion, positioning it among the largest global pharmaceutical companies, per SID market data. The stock trades at a price-to-earnings ratio of 33.06, which represents a premium relative to many healthcare sector peers, while its PEG ratio of 4.53 suggests that the current earnings multiple is elevated relative to its expected growth trajectory. The price-to-book ratio stands at 6.24, according to SEC filings, reflecting significant intangible asset value embedded in the company's oncology and biopharmaceutical pipeline. AstraZeneca offers a dividend yield of approximately 1.56%, providing a modest income component for shareholders. The combination of a high PE, elevated PEG ratio, and above-average price-to-book multiple indicates the market is pricing in substantial future revenue and earnings expansion from the company's late-stage drug development portfolio and recently launched therapies.
Smart Money Activity for AZN
AstraZeneca PLC registers a smart money composite score of 58 out of 100 with a neutral overall signal, per SID market data. Institutional ownership strength is the standout metric, scoring a perfect 25 out of 25, indicating significant conviction among large asset managers and fund complexes. Insider activity scores 12.5 out of 25, with SEC Form 4 filings showing two insider transactions over the past 90 days, both of which were purchases and zero sells, suggesting measured confidence among company executives. Congressional trading activity registers at 12 out of 25, reflecting moderate legislative interest in the name. Dark pool activity scores a relatively low 8.9 out of 25, according to 13F institutional filings and off-exchange data, which may indicate that large block transactions have been limited in recent weeks. The divergence between maximum institutional conviction and subdued dark pool activity presents a nuanced picture of current smart money positioning in AstraZeneca shares.
AstraZeneca PLC Earnings Outlook
AstraZeneca PLC has demonstrated a pattern of significant earnings outperformance in recent quarters, according to company earnings reports. In its most recently reported quarter, the company posted earnings of $2.63 per share against an analyst consensus estimate of $1.52, representing a positive surprise of $1.11 or approximately 73%. The prior quarter similarly exceeded expectations, delivering $2.58 per share versus an estimate of $1.53, a positive surprise of $1.05. Looking ahead, analyst estimates project earnings of $1.75 per share for the upcoming reporting period on April 28 and $1.44 per share for the following quarter with results expected on July 28. The consecutive beats of over $1.00 per share highlight strong operational execution. Analysts appear to maintain conservative forward estimates relative to recent actual results, which could position the company for continued upside surprises if current business momentum persists across its therapeutic portfolio.
Wall Street Analyst Ratings for AZN
Wall Street analyst sentiment on AstraZeneca PLC remains divided, according to recent coverage updates tracked by SID consensus data. Berenberg Bank reiterated a Buy rating on July 13, 2026, reinforcing a constructive outlook on the company's growth prospects. Jefferies has also maintained a Buy rating through two separate reiterations on June 9 and June 26, signaling sustained bullish conviction from the firm. In contrast, Deutsche Bank has taken a bearish stance, reiterating a Sell rating twice on June 11 and June 26, representing the primary dissenting voice among recent coverage actions. This creates a clear 3-to-2 ratio of Buy versus Sell reiterations across the five most recent analyst actions, per Wall Street analyst reports. The absence of Hold ratings in recent activity suggests analysts hold strong directional views on AZN rather than adopting neutral positions, reflecting ongoing debate about the sustainability of AstraZeneca's premium valuation amid its robust earnings trajectory.
